Stephane Bancel

Stephane Bancel, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Moderna, Inc. and Generate Biomedicines, Inc. Over a trading history stretching from 30 April 2021 to 6 August 2026, the count stands at 138 filings.

The open-market side counts 1 purchase for €3.1M alongside 66 sales for €127.4M. Sales outweigh purchases by €124.3M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 3 share grants and 62 option exercises. So far in 2026, the count stands at no purchases and 4 sales.

The latest filing, published on 7 August 2026, reports an option exercise of €8.3M in Moderna, Inc. The most recent open-market purchase was published on 4 March 2025, 593 days ago. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.